Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, focuses on developing novel therapies for autoimmune diseases and rare disorders. Founded in 2001, Momenta has made significant strides in the industry, particularly with its innovative approach to monoclonal antibodies and complex generics.
The company is renowned for its core product, M923, a biosimilar to a well-established therapeutic antibody, which exemplifies its commitment to providing high-quality, affordable treatment options. Momenta's unique expertise in molecular characterisation and analytical development sets it apart in the competitive biopharmaceutical landscape.
With a strong market position, Momenta has achieved notable milestones, including successful collaborations and advancements in its pipeline, reinforcing its reputation as a pioneer in the biotechnology sector.
+33 vs industry average
Momenta Pharmaceuticals, Inc.’s score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Momenta Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Momenta Pharmaceuticals, Inc. yet.
Momenta Pharmaceuticals, Inc.'s reported carbon emissions
Momenta Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation.
While no direct emissions figures are provided, Momenta Pharmaceuticals aligns with the sustainability initiatives of Johnson & Johnson, which has set ambitious climate targets. These include commitments to reduce greenhouse gas emissions across its operations, with a focus on Scope 1, 2, and 3 emissions. The initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its operational footprint and to engage suppliers in reducing their emissions.
Momenta Pharmaceuticals is also involved in various sustainability initiatives cascaded from Johnson & Johnson, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in climate action.
In summary, while specific emissions data for Momenta Pharmaceuticals is not available, the company is committed to sustainability through its association with Johnson & Johnson's comprehensive climate strategies and targets.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Momenta Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Momenta Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Johnson & Johnson
Carbon Disclosure Project
Inherited from Johnson & Johnson
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Johnson & Johnson
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Momenta Pharmaceuticals, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project